Olorinab in Irritable Bowel Syndrome With Predominant Constipation (IBS-C) and Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D)

Clinical trial NCT04043455 · TERMINATED

Trial details

NCT number: NCT04043455
Sponsor: Arena Pharmaceuticals
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Irritable Bowel Syndrome

Start date: 2019-07-24
Primary completion: 2021-04-29
Enrollment: 273

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.